FI20135701L - Pharmaceutically useful and safe combination for use in the treatment of diseases of importance - Google Patents

Pharmaceutically useful and safe combination for use in the treatment of diseases of importance Download PDF

Info

Publication number
FI20135701L
FI20135701L FI20135701A FI20135701A FI20135701L FI 20135701 L FI20135701 L FI 20135701L FI 20135701 A FI20135701 A FI 20135701A FI 20135701 A FI20135701 A FI 20135701A FI 20135701 L FI20135701 L FI 20135701L
Authority
FI
Finland
Prior art keywords
treatment
importance
diseases
pharmaceutically useful
safe combination
Prior art date
Application number
FI20135701A
Other languages
Finnish (fi)
Swedish (sv)
Inventor
Jukka T Salonen
Original Assignee
Mas Metabolic Analytical Services Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mas Metabolic Analytical Services Oy filed Critical Mas Metabolic Analytical Services Oy
Priority to FI20135701A priority Critical patent/FI20135701L/en
Priority to PCT/FI2014/050529 priority patent/WO2014207317A1/en
Publication of FI20135701L publication Critical patent/FI20135701L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention is directed to a combination comprising aspirin and vitamin D with antiarrhythmic, antiplatelet, antihypertensive and antineoplastic activity, for use in the prevention or treatment of a condition selected from the group consisting of arrhythmias, hypertension, coronary and cerebrovascular disease, congestive heart disease, peripheral artery disease and cancers, and to related personalized-health test kits.
FI20135701A 2013-06-26 2013-06-26 Pharmaceutically useful and safe combination for use in the treatment of diseases of importance FI20135701L (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20135701A FI20135701L (en) 2013-06-26 2013-06-26 Pharmaceutically useful and safe combination for use in the treatment of diseases of importance
PCT/FI2014/050529 WO2014207317A1 (en) 2013-06-26 2014-06-26 A pharmaceutically feasible and safe combination for use in the treatment of major diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20135701A FI20135701L (en) 2013-06-26 2013-06-26 Pharmaceutically useful and safe combination for use in the treatment of diseases of importance

Publications (1)

Publication Number Publication Date
FI20135701L true FI20135701L (en) 2014-12-27

Family

ID=51298783

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20135701A FI20135701L (en) 2013-06-26 2013-06-26 Pharmaceutically useful and safe combination for use in the treatment of diseases of importance

Country Status (2)

Country Link
FI (1) FI20135701L (en)
WO (1) WO2014207317A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180118A1 (en) * 2020-03-11 2021-09-16 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
WO2022124961A1 (en) * 2020-12-07 2022-06-16 Jacobsson Bo Christer A composition comprising a vitamin d and acetylsalicylic acid.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US6703380B2 (en) * 1999-09-29 2004-03-09 Colotech A/S Prevention of cancer
ATE444072T1 (en) * 2001-04-05 2009-10-15 Colotech As PREVENTION OF EPITHELIAL CELL CARCINOMA
WO2006074226A2 (en) * 2005-01-05 2006-07-13 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

Also Published As

Publication number Publication date
WO2014207317A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
CY1124436T1 (en) BICYCLIC HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
DOP2015000246A (en) DERIVATIVES OF REPLACED OXOPIRIDINE AND USES OF THE SAME IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
CL2016001629A1 (en) Tricyclic compounds as anticancer agents
UY34305A (en) DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
UY34566A (en) 1,4? DIHYDROPIRIMIDINES 4.4? DISUSTITUTED AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
UY34657A (en) ? MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES ?.
GT201400085A (en) ADRENOMEDULINE PROMOTE BASED ON POLYETHYLENE GLYCOL AND ITS USE
UY35747A (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE
CL2015002346A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-carboxamides for the inhibition of 17b-hydroxysteroid dehydrogenase (akr1 c3)
CU20160032A7 (en) SUBSTITUTED PHENYLALANINE DERIVATIVES
CL2015000039A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-substituted derivatives, pharmaceutical preparations that comprise them and their use in the preparation of medicaments for treating endometriosis.
UY35745A (en) SUBSTITUTED DERIVATIVES OF PHENYLALANINE
CO2017002813A2 (en) Stabilized derivatives of adrenomedullin and their use
UY34543A (en) DERIVATIVES OF SULFONYLAMINOPIRROLIDINONE, ITS PREPARATION AND THERAPEUTIC APPLICATION.
FI20135701L (en) Pharmaceutically useful and safe combination for use in the treatment of diseases of importance
CR20150659A (en) DERIVATIVES OF PRODUCTION OF SUBSTITUTED TRIAZOLPIRIDINES
EA201391438A1 (en) DERIVATIVES OF SULINDAC, APPLICATION AND OBTAINING OF THE INDICATED DERIVATIVES
ES2543850R2 (en) Use of SOD mimetic metal complexes as food agents and as cosmetics
UA112488C2 (en) THREE (HETERO) ARILPYRAZOLES AND THEIR APPLICATIONS
CA149198S (en) Organ or tissue cradle
UY37139A (en) VINORELBIN MONOTARTRATE AND ITS PHARMACEUTICAL USE
CL2020001559A1 (en) Glucosidic derivatives of treprostinil.
CO2019011285A2 (en) N-arylethyl-2-arylquinoline -4-substituted carboxamides and their use
EA201692013A1 (en) NEW APPLICATION N, N-BIS-2-MERCAPTOETHYL-ISOPHTHALAMIDE
CA149197S (en) Organ or tissue cradle

Legal Events

Date Code Title Description
FD Application lapsed